diabetestalk.net

What Is The Fastest Acting Insulin

Fast-acting Insulin, Fiasp, Gets Fda Approval

Fast-acting Insulin, Fiasp, Gets Fda Approval

Recently, the U.S. Food and Drug Administration approved Novo Nordisk’s latest fast-acting insulin, Fiasp, for treatment use by adults with diabetes. The move makes available a product that should allow those with T1D to better meet their target A1C levels by controlling post-meal blood sugar spikes. Fiasp, which is a fast-acting insulin asparte, is designed for dosing at the start of a meal or within 20 minutes of beginning to eat. The insulin registers in the blood stream as quickly as two and a half minutes after application. “Generally individuals are well controlled in long insulin,” said Dr. Todd Hobbs, Novo Nordisk’s Chief Medical Officer for North America. “But being able to hold down and keep the meal excursions from rising is going to have an effect on A1C. When individuals get close to their A1C goals — hit seven or eight — but can’t quite get over the hump, most of the time the barrier is meals.” Fiap grew out of the company’s previous fast-acting insulin product, NovoLog. With Fiasp the company improved the speed of initial insulin absorption rates by adding niacinamide (vitamin B3). “With Fiasp we’ve built on the insulin aspart molecule to create a new treatment option to help patients meet their post-meal blood sugar target,” said Dr. Bruce Bode, President of Atlanta Diabetes Associates and an Associate Professor at Emory University School of Medicine. Insulin aspart is a synthetic insulin manufactured from human insulin. A single amino acid is changed in the insulin’s chemical composition to help the insulin be absorbed into the body more quickly. The traditional knock against fast-acting insulin is that’s it’s also fast going, wearing off quickly as well. With Fiasp, Novo Nordisk believes it can continue counteracting tha Continue reading >>

Novo Nordisk’s Ultra-fast Rapid-acting Insulin Fiasp Approved In Europe And Canada

Novo Nordisk’s Ultra-fast Rapid-acting Insulin Fiasp Approved In Europe And Canada

Novo Nordisk has announced that their ultra-fast rapid-acting insulin aspart called Fiasp has been approved by the European Commission, covering all 28 European Union member states. According to a GlobeNewswire press release, Fiasp is a new-generation mealtime insulin that works faster and more like the natural physiological insulin response to meals. It has a similar safety profile to Novolog insulin in the US and NovoRapid in the UK and is approved for the treatment of diabetes in adults with type 1 or 2 diabetes as well as for use in insulin pumps. About Ultra-Fast Fiasp Insulin Fiasp is a faster formulation of insulin aspart (Novolog/NovoRapid). It is able to provide “earlier, greater and faster absorption, thereby providing earlier insulin action.” The executive vice president and chief science officer of Novo Nordisk, Mads Krogsgaard said in the press release that, “The incremental benefits with Fiasp® are comparable to those observed for the last generation of mealtime insulins when introduced more than a decade ago.” Krogsgaard is referring to how faster insulin analogs were introduced a little over a decade ago and we saw a great improvement in blood sugar management surrounding meals over the older Regular human insulin. Now it looks like the age of ultra-fast rapid-acting insulin is upon us and bringing another potential improvement in blood sugar management. Fiasp will be available by vial, Penfill, and FlexTouch insulin pen. Effectiveness and Safety of Fiasp EPGOnline reported about the trials conducted comparing Fiasp with insulin aspart (Novolog/NovoRapid). Results from the final Phase IIIa trials called ONSET 1 and ONSET 2 revealed that for people with type 1 diabetes, Fiasp was much more statistically likely to lower HbA1c levels than insulin a Continue reading >>

What Is Novolog

What Is Novolog

®? NovoLog® helps improve blood sugar control in people with diabetes. It is used to help lower blood sugar in adults and children with type 1 diabetes (aged 2 years and older) and adults with type 2 diabetes. But you may hear your health care provider refer to it by a few other names: As an insulin that you take at mealtime, NovoLog® is usually called “mealtime” or "bolus" insulin Because it goes to work quickly, it is also sometimes called “rapid-acting” or “fast-acting” insulin It is also called "analog insulin" because it is a man-made insulin that is a slightly changed version of the insulin your body makes naturally All of these things are true. What is NovoLog®? NovoLog® is a fast-acting mealtime insulin that helps lower mealtime blood sugar spikes. It has been proven to help control high blood sugar in people with diabetes when taken with a long-acting insulin. And, it has been used by millions of people since 2001. NovoLog® is fast-acting and works to help control blood sugar spikes when you eat. You should take NovoLog® and eat within 5 to 10 minutes. So you don’t have to wait 30 minutes before you eat, like you would with regular human insulin. Controlling your blood sugar at mealtime with NovoLog® can help lower your A1C when taken with a long-acting insulin. And, NovoLog® has a low rate of low blood sugar (also known as hypoglycemia). Keep in mind that low blood sugar is a common side effect of all insulins, including NovoLog®. NovoLog® is a fast-acting analog insulin, but it is not the only analog insulin. Different types of analog insulin are available. Each type of insulin helps keep diabetes under control. But no one type is right for everyone. Each person's insulin needs are different. And each person's insulin needs may change Continue reading >>

Fda Approves New Fast-acting Mealtime Insulin

Fda Approves New Fast-acting Mealtime Insulin

Officials with the FDA have approved fast-acting insulin aspart (Fiasp, Novo Nordisk) for the treatment of adults with diabetes. Fiasp is a fast-acting mealtime insulin designed for individuals in need of improved overall glucose control. Fiasp, a formulation of insulin aspart, was developed to more closely match the physiological insulin mealtime response of an individual with diabetes. Vitamin B3 (niacinamide) and a naturally occurring amino acid (L-Arginine) were added to increase the speed of absorption and for stability, respectively. The approval is based on clinical trials that demonstrated Fiasp’s clinically relevant improvement in long-term glucose level. The trial researchers noted comparable overall rate of severe or blood sugar confirmed hypoglycemia between Fiasp and aspart. The phase 3 clinical program included 4 trials with more than 2100 individuals with type 1 and type 2 diabetes. According to data presented recently at the 53rd European Association for the Study of Diabetes Annual Meeting, in the onset 1 trial, Fiasp was compared to conventional insulin aspart in type 1 diabetes over a 52-week study, split in two 26-week treatment periods. Over the 52-week period, Fiasp demonstrated a statistically significant greater overall blood sugar reduction of -0.10% adults with type 1 diabetes, in comparison to conventional insulin aspart. Fiasp also demonstrated a statistically significant reduction in 1-hour post-meal sugar increment of -0.91 mmol/L. However, no significant differences were noted in 2-hour post-meal sugar increment compared with conventional insulin aspart. Novo Nordisk received a Complete Response Letter (CRL) from the FDA for Fiasp in October 2016, and later resubmitted the new drug application on March 29, 2017. In this video taken durin Continue reading >>

What Is Rapid Or Fast-acting Insulin?

What Is Rapid Or Fast-acting Insulin?

You may take rapid acting or fast acting insulin (also known as insulin analogues) for your diabetes, either through injections prior to your meals, or in your insulin pump. You may use it alone, or in combination with other insulins and diabetes medications, including injections and pills. In a person without diabetes, the pancreas puts out small amounts of insulin, continuously bringing down blood sugars to a normal level with no difficulty. When a person has diabetes, they may not make any insulin, as occurs in Type 1 Diabetes. They may make some insulin, but it’s not working well, and it’s just not enough to bring blood sugars into a normal range, as occurs in Type 2 Diabetes. When there is no insulin, or not enough insulin, the goal is to try to simulate what the body normally does to bring down blood sugars through injections of insulin, inhaled insulin, or via an insulin pump. To do this, rapid or fast acting insulin must be taken in relation to food that is eaten in many cases. Not everyone with diabetes must take insulin to control their blood sugars, though. Let’s learn how Christie uses rapid acting insulin… Christie’s story Christie has had Type 1 Diabetes for 24 years. She uses a Medtronic insulin pump. Every day, Christie’s pump gives her fast or rapid acting insulin. This is all that insulin pumps need to control blood sugar. For Christie, she uses Humalog lispro insulin. She gets a little bit of this rapid or fast acting insulin continually through her pump via a basal. She also gets some of this insulin through her pump, in a bolus dose every time she eats a meal. In a pump, the same insulin is used all the time, and it is always rapid insulin. Christie also has a new Continuous Glucose Monitor, CGM. She has found with this new technology, s Continue reading >>

About Fast-acting Mealtime Insulin

About Fast-acting Mealtime Insulin

What is mealtime insulin? Mealtime insulins are fast-acting insulins that are taken immediately before or after meals. As you eat, your blood sugar naturally goes up, or “spikes.” Humalog® (a fast-acting insulin) works to manage those blood sugar spikes and may help keep your sugar levels in balance. Humalog should be taken within 15 minutes before eating or right after eating a meal. People who take Humalog will usually continue to take longer-acting insulin to help manage blood sugar levels at night and between meals. Taking mealtime insulin in addition to longer-acting insulin may help to control blood sugar levels throughout the day. Low blood sugar (hypoglycemia) is the most common side effect of Humalog that may be severe and cause unconsciousness (passing out), seizures, and death. Test your blood sugar levels as your doctor instructs. Talk to your doctor about low blood sugar symptoms and treatment. The orange area shows how blood sugar levels typically rise after meals. The pattern of insulin action may vary in different individuals or within the same individual. Comparing types of insulin Take a look at our overview below to find out about the different types of insulin. You’ll notice that there are differences in when the types of insulin reach your bloodstream, when they “peak” in your body, and how long they can last (length of time the insulin keeps lowering your blood sugar). Fast-acting insulin (also called rapid-acting) is absorbed quickly and starts working in about 15 minutes to lower blood sugar after meals. Humalog fast-acting insulin should be taken 15 minutes before eating or right after eating a meal. Depending on the type of diabetes you have, you may need to take Humalog with a longer-acting insulin or oral anti-diabetes medication. Continue reading >>

Types Of Insulin For Diabetes Treatment

Types Of Insulin For Diabetes Treatment

Many forms of insulin treat diabetes. They're grouped by how fast they start to work and how long their effects last. The types of insulin include: Rapid-acting Short-acting Intermediate-acting Long-acting Pre-mixed What Type of Insulin Is Best for My Diabetes? Your doctor will work with you to prescribe the type of insulin that's best for you and your diabetes. Making that choice will depend on many things, including: How you respond to insulin. (How long it takes the body to absorb it and how long it remains active varies from person to person.) Lifestyle choices. The type of food you eat, how much alcohol you drink, or how much exercise you get will all affect how your body uses insulin. Your willingness to give yourself multiple injections per day Your age Your goals for managing your blood sugar Afrezza, a rapid-acting inhaled insulin, is FDA-approved for use before meals for both type 1 and type 2 diabetes. The drug peaks in your blood in about 15-20 minutes and it clears your body in 2-3 hours. It must be used along with long-acting insulin in people with type 1 diabetes. The chart below lists the types of injectable insulin with details about onset (the length of time before insulin reaches the bloodstream and begins to lower blood sugar), peak (the time period when it best lowers blood sugar) and duration (how long insulin continues to work). These three things may vary. The final column offers some insight into the "coverage" provided by the different insulin types in relation to mealtime. Type of Insulin & Brand Names Onset Peak Duration Role in Blood Sugar Management Rapid-Acting Lispro (Humalog) 15-30 min. 30-90 min 3-5 hours Rapid-acting insulin covers insulin needs for meals eaten at the same time as the injection. This type of insulin is often used with Continue reading >>

Fda Approves Novo Nordisk Fast-acting Insulin Fiasp

Fda Approves Novo Nordisk Fast-acting Insulin Fiasp

(Reuters) - The U.S. Food and Drug Administration on Friday approved Novo Nordisk’s fast-acting insulin to treat diabetes. The product, known as Fiasp, is designed to help diabetics control post-meal spikes in blood sugar. It is already approved in Canada and Europe. Fiasp, or faster acting insulin asparte, is designed to work faster than existing fast-acting insulin such as Eli Lilly and Co’s Humalog and Novo Nordisk’s own NovoLog, known as NovoRapid outside the United States. Last year the FDA declined to approve the product and requested additional information. Continue reading >>

Insulin A To Z: A Guide On Different Types Of Insulin

Insulin A To Z: A Guide On Different Types Of Insulin

Elizabeth Blair, A.N.P., at Joslin Diabetes Center, helps break down the different types of insulin and how they work for people with diabetes. Types of Insulin for People with Diabetes Rapid-acting: Usually taken before a meal to cover the blood glucose elevation from eating. This type of insulin is used with longer-acting insulin. Short-acting: Usually taken about 30 minutes before a meal to cover the blood glucose elevation from eating. This type of insulin is used with longer-acting insulin. Intermediate-acting: Covers the blood glucose elevations when rapid-acting insulins stop working. This type of insulin is often combined with rapid- or short-acting insulin and is usually taken twice a day. Long-acting: This type of insulin is often combined, when needed, with rapid- or short-acting insulin. It lowers blood glucose levels when rapid-acting insulins stop working. It is taken once or twice a day. A Guide on Insulin Types for People with Diabetes Type Brand Name Onset (length of time before insulin reaches bloodstream) Peak (time period when insulin is most effective) Duration (how long insulin works for) Rapid-acting Humalog Novolog Apidra 10 - 30 minutes 30 minutes - 3 hours 3 - 5 hours Short-acting Regular (R) 30 minutes - 1 hour 2 - 5 hours Up to 12 hours Intermediate- acting NPH (N) 1.5 - 4 hours 4 - 12 hours Up to 24 hours Long-acting Lantus Levemir 0.8 - 4 hours Minimal peak Up to 24 hours To make an appointment with a Joslin diabetes nurse educator, please call (617) 732-2400. Continue reading >>

Just How Quick Is Fiasp, Novo Nordisk’s Faster-acting Insulin?

Just How Quick Is Fiasp, Novo Nordisk’s Faster-acting Insulin?

Fiasp, a new, faster-acting insulin from Novo Nordisk, is generating a lot of interest and carries with it much potential for improved diabetes care. A sort of acronym for faster acting insulin asparte, Fiasp starts working within two minutes of injection and can even be effective in lowering blood sugar when taken up to 20 minutes after a meal. Existing fast-acting insulin formulations such as Humalog, Apidra and Novo Nordisk’s own NovoLog (called NovoRapid in Europe and Canada), take 10 to 20 minutes to begin lowering blood sugar after injection. According to Novo Nordisk, Fiasp, “has its maximum effect between 1 and 3 hours after the injection and the effect lasts for 3 to 5 hours.” “Our goal in developing Fisap was to try and get closer to mimicking the body’s own insulin response to food,” says Michael Bachner, Associate Director for Product Communications for Novo Nordisk. “Doing that creates a lot of opportunities for how this might be applied to improve care.” Fiasp was approved for use in Europe in January and approved in Canada in late March. Approval in the United States is pending with Novo Nordisk expecting to hear back form the FDA in the fourth quarter of this year, Bachner says. (The FDA application is the Danish pharmacy giant’s second attempt at U.S. approval.) Interest in the new insulin is keen, according to chat boards and as reported by Mike Hoskins for the DiabetesMine team in late April. Tim Street, a diabetes writer, reports an uptick in views to his site since he started reporting on Fiasp. His website diabettech.com—“Where diabetes and technology meet”—says when he started writing about Fiasp visits to his site went from between 200 and 500 per day to between 500 and 1,000 per day. To date, Street has penned six artic Continue reading >>

Fiasp® (insulin Aspart Injection) 100 U/ml Indications And Usage

Fiasp® (insulin Aspart Injection) 100 U/ml Indications And Usage

Fiasp® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to Fiasp® or one of its excipients. Never share a Fiasp® FlexTouch® Pen between patients, even if the needle is changed. Patients using Fiasp® vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens. Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased. Fiasp® (insulin aspart injection) 100 U/mL is a rapid-acting insulin analog indicated to improve glycemic control in adults with diabetes mellitus. Fiasp® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to Fiasp® or one of its excipients. Never share a Fiasp® FlexTouch® Pen between patients, even if the needle is changed. Patients using Fiasp® vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens. Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased. Hypoglycemia is the most common adverse reaction of insulin, including Fiasp®, and may be life-threatening. Increase glucose monitoring with changes to: insulin dosage, co-administered glucose lowering medications, meal pattern, physical activity; and in patients with renal impairment or hepatic impairment or hypoglycemia unawarenes Continue reading >>

Ultra-fast Acting Insulin Analogues.

Ultra-fast Acting Insulin Analogues.

Abstract Insulin analogues are a major improvement in diabetes pharmacotherapy. Rapid acting insulins have certain advantages over regular insulin, but there is a need to develop even faster acting insulin preparations, which mimic physiological insulin release in a better manner. This review discusses recent developments and patents in the field of Ultra- fast acting insulins. It classifies various approaches towards creation of an Ultra-fast acting insulin profile based upon the method used to achieve a faster onset of action. These include change in formulation of insulin, addition of excipients to insulin, and utilization of novel insulin sites or delivery methods. It examines the current state of evidence, and the developments in the field of newer insulin analogues & delivery methods. Continue reading >>

Rapid Acting Insulin

Rapid Acting Insulin

Tweet Rapid acting insulins are usually taken just before or with a meal. They act very quickly to minimise the rise in blood sugar which follows eating. Rapid acting insulins are commonly prescribed to people with type 1 diabetes, however, there may be times when they can be prescribed for type 2 diabetes as well. As rapid acting insulins act very quickly, they can lead to an increased chance of hypoglycemia. Care should be therefore taken when dosing. What type of insulin is a rapid acting insulin? Rapid insulins, which are a type of insulin known as analogue insulins, can either be injected or delivered via an insulin pump. Humalog Humalog is an Eli Lilly product, with the active ingredient insulin lispro. It is extremely rapid-acting, and will typically begin to work within 15 minutes. Effects of the insulin last for between 2 and 5 hours. It is faster-acting than soluble insulin, and is therefore extremely useful around mealtimes. Like many other rapid-acting forms of insulin, humalog may be combined with intermediate or longer-acting insulin for a longer period of blood glucose maintenance. Novorapid The active ingredient in Novorapid is insulin aspart. When novorapid is injected, it is extremely fast-acting, and works rapidly to normalise blood sugar levels. It typically begins working after 10-20 minutes, and will last for between 3 and 5 hours. It may be injected before a meal, and sometimes immediately after, to ensure strict control of post-prandial levels. Often, insulin aspart formulations such as novorapid will be combined with other longer lasting (intermediate-acting and longer-acting) insulin. In this way, control over blood glucose levels can be maintained throughout the day. Tweet Type 2 diabetes mellitus is a metabolic disorder that results in hyperg Continue reading >>

Fast-acting Insulin

Fast-acting Insulin

Even when you think you’re doing everything right with your diabetes care regimen, it can sometimes seem like your blood glucose levels are hard to control. One potential source of difficulty that you may not have thought of is how you time your injections or boluses of rapid-acting insulin with respect to meals. Since the first rapid-acting insulin, insulin lispro (brand name Humalog), came on the market in 1996, most diabetes experts have recommended taking it within 15 minutes of starting a meal (any time between 15 minutes before starting to eat to 15 minutes after starting to eat). This advice is based on the belief that rapid-acting insulin is absorbed quickly and begins lowering blood glucose quickly. However, several years of experience and observation suggest that this advice may not be ideal for everyone who uses rapid-acting insulin. As a result, the advice on when to take it needs updating. Insulin basics The goal of insulin therapy is to match the way that insulin is normally secreted in people without diabetes. Basal insulin. Small amounts of insulin are released by the pancreas 24 hours a day. On average, adults secrete about one unit of insulin per hour regardless of food intake. Bolus insulin. In response to food, larger amounts of insulin are secreted and released in two-phase boluses. The first phase starts within minutes of the first bite of food and lasts about 15 minutes. The second phase of insulin release is more gradual and occurs over the next hour and a half to three hours. The amount of insulin that is released matches the rise in blood glucose from the food that is eaten. In people with normal insulin secretion, insulin production and release is a finely tuned feedback system that maintains blood glucose between about 70 mg/dl and 140 mg/d Continue reading >>

A Newer, Faster-acting Insulin? (faster Than Novolog!)

A Newer, Faster-acting Insulin? (faster Than Novolog!)

New findings from phase 3a trials show that a faster-acting insulin aspart by Novo Nordisk reduced A1c levels and improved after meal blood sugars in people with type 1 and 2 diabetes compared with NovoLog. These findings were presented at the 76th annual Scientific Sessions of the American Diabetes Association (ADA) in New Orleans. Novolog (also marketed as Novorapid) is a fast-acting insulin aspart. The trial involves 2,100 people with type 1 and 2 diabetes and an even faster-acting insulin aspart. The trial consisted of 26 weeks of randomized therapy using a faster-acting insulin aspart which showed statistically significantly improved A1c in adults with type 1 diabetes when dosed at mealtime compared with Novolog. A similar result in A1c improvement was found when the insulin aspart was dosed 20 minutes after a meal compared with Novolog. What is Faster-Acting Insulin Aspart? Faster-acting insulin aspart is a fast acting bolus or mealtime insulin in investigation stages developed by Novo Nordisk. It is also insulin aspart like Novolog (or Novorapid) but in a new formulation which includes a vitamin and an amino acid intended to increase the initial absorption rate and provide a faster and earlier blood sugar lowering effect. “Novo Nordisk has submitted the regulatory filing for faster-acting insulin aspart in the United States and in the European Union.” How Did the Faster-Acting Insulin Aspart Work in Type 1 Diabetics? The trial also showed a reduction in 2-hour PPG increment versus Novolog. In addition, 1-hour PPG increment was also reduced. The 2-hour PPG increment is the difference between the plasma glucose value at 120 minutes after a standard meal test and the fasting plasma glucose value. The 1-h PPG increment is the difference between the plasma glucose Continue reading >>

More in insulin